The ISSCR Shares Comments on the European Medicines Agency's Network Strategy to 2025

Among other points made, the ISSCR recognized that the draft network strategy acknowledges the lack of consistency across the EU for how some products are regulated, and encouraged the EMA to prioritize the consistent application of the regulations and enforcement to prevent the premature commercialization of stem cell-based products and other regenerative medicines.
Read the letter.